Should azithromycin be used to treat COVID-19? A rapid review

Gbinigie, Oghenekome; Frie, Kerstin

doi:10.3399/bjgpopen20x101094

Cited by 42 publications

(40 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also found that none of the other dedicated drugs used in this quasi-experimental study was associated with better survival rate in COVID-19 patients. The interest of these drugs in COVID-19 is still debated, whether for corticosteroids [ 26 ], hydroxychloroquine [ 27 ] or azithromycin [ 28 ]. However, it should be noted that these drugs were given here as part of patient care in the most severe clinical situations, which could have biased and masked their effectiveness (if any).…”

Section: Discussionmentioning

confidence: 99%

Vitamin D and survival in COVID-19 patients: A quasi-experimental study

Annweiler

Hanotte

l'Eprevier³

et al. 2020

The Journal of Steroid Biochemistry and Molecular Biology

197

208

View full text Add to dashboard Cite

Highlights Vitamin D may be a central biological determinant of COVID-19 outcomes. Bolus vitamin D3 supplementation during or just before COVID-19 was associated with less severe COVID-19 in frail elderly. Bolus vitamin D3 supplementation during or just before COVID-19 was associated with better survival rate in frail elderly. Randomized controlled trials are expected to firmly conclude the effect of vitamin D supplementation on COVID-19 prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Vitamin D and survival in COVID-19 patients: A quasi-experimental study

Annweiler

Hanotte

l'Eprevier³

et al. 2020

The Journal of Steroid Biochemistry and Molecular Biology

197

208

View full text Add to dashboard Cite

show abstract

“… 7 , 19 , 23 , 25 , 28 , 31 – 33 , 43 , 47 , 54 , 56 , 60 Macrolides (e.g. azithromycin), 9 , 10 , 18 , 19 , 22 , 23 , 25 , 33 , 36 , 42 , 47 , 49 , 52 , 55 , 58 , 59 fluoroquinolone (e.g. moxifloxacin, 19 , 23 , 28 , 31 , 33 , 41 , 47 , 60 levofloxacin), 31 , 44 , 47 glycopeptides (e.g.…”

Section: Resultsmentioning

confidence: 99%

Therapeutic interventions for COVID-19: a living overview of reviews

Khalili

Chegeni

Javadi

et al. 2020

Ther Adv Respir Dis

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide, but safe and effective treatment options remain unavailable. Numerous systematic reviews of varying qualities have tried to summarize the evidence on the available therapeutic interventions for COVID-19. This overview of reviews aims to provide a succinct summary of the findings of systematic reviews on different pharmacological and non-pharmacological therapeutic interventions for COVID-19. Methods: We searched PubMed, Embase, Google Scholar, Cochrane Database of Systematic Reviews, and WHO database of publications on COVID-19 from 1 December 2019 through to 11 June 2020 for peer-reviewed systematic review studies that reported on potential pharmacological or non-pharmacological therapies for COVID-19. Quality assessment was completed using A MeaSurement Tool to Assess systematic Reviews-2 (AMSTAR-2) measure. Results: Out of 816 non-duplicate studies, 45 were included in the overview. Antiviral and antibiotic agents, corticosteroids, and anti-malarial agents were the most common drug classes used to treat COVID-19; however, there was no direct or strong evidence to support their efficacy. Oxygen therapy and ventilatory support was the most common non-pharmacological supportive care. The quality of most of the included reviews was rated as low or critically low. Conclusion: This overview of reviews demonstrates that although some therapeutic interventions may be beneficial to specific subgroups of COVID-19 patients, the available data are insufficient to strongly recommend any particular treatment option to be used at a population level. Future systematic reviews on COVID-19 treatments should adhere to the recommended systematic review methodologies and ensure that promptness and comprehensiveness are balanced. The reviews of this paper are available via the supplemental material section.

show abstract

“…Initiate oxygen therapy at 5 L/min and titrate flow rates to reach target SpO2 ≥ 93% during resuscitation; or use face mask with reservoir bag (at 10-15 L/min) if patient in critical condition. Once patient is stable, the target is > 90% SpO2 in non-pregnant adults [94] and ≥ 92-95% in pregnant patients [106,107].…”

Section: Other Agents Under Investigationmentioning

confidence: 99%

The SARS-COV2 (COVID-19) Pandemic: What Clinicians should knew

Saeed

Zaher

Khorshed

et al. 2020

Afro-Egyptian Journal of Infectious and Endemic Diseases

View full text Add to dashboard Cite

In late 2019, a novel coronavirus, now designated SARS-CoV-2, emerged and was identified as the cause of an outbreak of acute respiratory illness in Wuhan, a city in China, named as COVID-19. Since then the waves of the virus exponentially hit many countries around the globe with high rates of spread associated with variable degrees of morbidity and mortality. The WHO announced the pandemic state of the infection in March 2020 and by June 1st 2020 more than 6 million individuals and more than 370 thousands case fatalities were documented worldwide. In this article, we discussed many aspects regarding this emerged infection based on the available evidence aiming to help clinician to improve not only their knowledge but also their practices toward this infection.

show abstract

Should azithromycin be used to treat COVID-19? A rapid review

Abstract: Background: There are no established effective treatments for COVID-19. While novel drugs are being developed, azithromycin has been identified as a candidate treatment in the interim.Aim: To review the evidence for the effectiveness and safety of azithromycin in treating COVID-19.

Cited by 42 publications

References 17 publications

Vitamin D and survival in COVID-19 patients: A quasi-experimental study

Vitamin D and survival in COVID-19 patients: A quasi-experimental study

Therapeutic interventions for COVID-19: a living overview of reviews

The SARS-COV2 (COVID-19) Pandemic: What Clinicians should knew

Contact Info

Product

Resources

About